相关实验视频
Updated: Jul 14, 2026

06:44
Cantilever Bending of Murine Femoral Necks
Published on: January 5, 2022
超低剂量微化17β-雌激醇和老年女性的骨密度和骨代谢:一项随机对照试验
Karen M Prestwood1, Anne M Kenny, Alison Kleppinger
1Center on Aging, University of Connecticut Health Center, Farmington 06030, USA. Prestwood@nso1.uchc.edu
JAMA
|August 28, 2003
概括
低剂量雌激素疗法 (0.25 mg/d 17β-雌激素) 有效地增加了骨矿物密度,并减少了健康的老年绝经后妇女在三年内骨周转率. 这种治疗显示出最小的不良影响,这表明它是预防骨质疏松症的安全有效选择.
科学领域:
- 内分泌学 在内分泌学.
- 老年学是一门学科.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 雌激素治疗已被认可用于骨质疏松症的预防.
- 传统剂量与不良事件有关.
- 低剂量雌激素 (0.25 mg/d) 预防骨质损失的疗效仍未确立.
研究的目的:
- 评估0.25 mg/d微化17β-雌激醇对骨矿物质密度 (BMD) 和骨周转的影响.
- 为了在健康的,年长的绝经后妇女中评估3年治疗期间的这些影响.
主要方法:
- 一个为期3年的随机,双盲,安慰剂对照试验.
- 这项研究涉及167名65岁以上的健康女性.
- 每年测量BMD;评估骨循环和激素水平的生化标志物在基线,3个月,1年和3年.
主要成果:
- 与安慰剂相比,低剂量雌激素显著增加了部,脊椎和全身的BMD (P<.001).
- 骨循环标记物 (N-端粒,骨性酸酶) 在低剂量雌激素 (P<.001) 时显著下降.
- 两组间的不良事件概况相似,乳房敏感度,子宫内膜变化或乳房扫描结果没有显著差异.
结论:
- 低剂量的17β-雌二醇 (0.25 mg/d) 有效地增加骨密度,并减少老年妇女的骨周转.
- 该疗法表现出了有利的安全性概况,副作用最小.
- 需要进一步的研究来调查低剂量雌激素对骨折预防的影响.
相关概念视频
Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

